Pharmacological therapy in children with atrioventricular reentry: Which drug?

Current Pharmaceutical Design

Volumn 14, Issue 8, 2008, Pages 753-761

  Ratnasamy, Christopher ^a   Rossique Gonzalez, Marie ^a   Young, Ming Lon ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Arrhythmia; Atenolol; Metoprolol; Nadolol; SVT; Wolff Parkinson White; WPW

Indexed keywords

ADENOSINE; AMIODARONE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIGOXIN; ESMOLOL; FLECAINIDE; METOPROLOL; NADOLOL; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; SOTALOL; VERAPAMIL;

ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRONCHOSPASM; CATHETER ABLATION; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL TRIAL; CONTINUOUS INFUSION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CHOICE; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; ELECTROCARDIOGRAM; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART ACCESSORY CONDUCTION PATHWAY; HEART ARRHYTHMIA; HEART ATRIOVENTRICULAR NODE; HEART FUNCTION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; HYPERTHYROIDISM; HYPOTENSION; HYPOTHYROIDISM; INTERSTITIAL PNEUMONIA; LETHARGY; LIVER TOXICITY; LOADING DRUG DOSE; LUNG FIBROSIS; LUNG TOXICITY; MONOTHERAPY; NAUSEA; NIGHTMARE; OPTIC NEURITIS; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REENTRY TACHYCARDIA; REVIEW; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; VOMITING;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; CATHETER ABLATION; CHILD; CHRONIC DISEASE; HUMANS; TACHYCARDIA, ATRIOVENTRICULAR NODAL REENTRY; WOLFF-PARKINSON-WHITE SYNDROME;

EID: 44349158341     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784007644     Document Type: Review

References (69)

1. Lubbers WJ, Losekoot TG, Anderson RH, Wellens HJ. Paroxysmal supraventricular tachycardia in infancy and childhood. Eur J Cardiol 1974; 2: 91-9.
2. Ko JK, Deal BJ, Strasburger JF, Benson DW Jr. Supraventricular tachycardia mechanisms and their age distribution in pediatric patients. Am J Cardiol 1992; 69(12): 1028-32.
3. Delacrétaz E. Clinical practice. Supraventricular tachycardia. N Engl J Med 2006; 354(10): 1039-51.
4. Deal BJ. In: Deal B, Wolff G, Gelband H Eds. Current concents in diagnosis and management of arrhythmias in infants and children. Armonk, NY: Futura Publishing Co., Inc. 1998; 117-43.
5. Garson A Jr, Kanter RJ. Management of the child with Wolff-Parkinson-White syndrome and supraventricular tachycardia: Model for cost effectiveness. J Cardiovasc Electrophysiol 1997; 8: 1320-6
6. Friedman RA, Walsh EP, Silka MJ, Calkins H, Stevenson WG, Rhodes LA, et al. NASPE Expert Consensus on Coference: Radiofrequency catheter ablation in children with and without congenital heart disease. Pacing Clin Electrophysiol 2002; 25: 1000-17.
7. Paul T. Kakavand B, Blaufox AD, Saul JP. Complete occlusion of the left circumflex coronary artery after radiofrequency catheter ablation in an infant. J Cardiovasc Electrophysiol 2003; 14: 1004-6.
8. Saul JP, Hulse JE, Papagiannis J, Van Praagh R, Walsh EP. Late enlargement of radiofrequency lesions in infant lambs. Implications for ablation procedures in small children. Circulation 1994; 90: 492-9.
9. Till J, Shinebourne EA, Rigby ML, Clarke B, Ward DE, Rowland E. Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in intants and children. Br Heart J 1989; 62: 204-11.
10. Perry JC. In: Deal B, Wolff G, Gelband H Eds. Current concepts in diagnosis and management of arrhythmias in infants and children. Armonk, NY: Futura Publishing Co., Inc. 1998: 267-308.
11. Kugler JD, Danford DA. Management of infants, children, and adolescents with paroxysmal supraventricular tachycardia. J Pediatr 1996; 129; 324-38.
12. Dixon J, Foster K, Wyllie J, Wren C. Guidelines qnd adenosine dosing in supraventricular tachycardia. Arch Dis Child 2005; 90: 1190-1.
13. Mulla N, Karpawich PP. Ventricular fibrillation following adenosine therapy for supraventricular tachycardi in a neonate with concealed Wolff-Parkinson-White syndrome treated with digoxin. Pediatr Emerg Care 1995; 11: 238-9.
14. Overholt ED, Rheuban KS, Gutgesell HP, Lerman BB, DiMarco JP. Usefulness of adenosine for arrhythmias in infants and children. Am J Cardiol 1988; 61: 336-40.
15. Wren C, Campbell R.W. The response of paediatric arrhythmias to intravenous and oral flecamide. Br Heart J 1987; 57: 171-5.
16. O'Sullivan JJ, Gardiner HM, Wren C. Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants? J Am Coll Cardiol 1995; 26: 991-4.
17. Musto B. D'Onofrio A, Cavallaro C, Musto A, Greco R. Electro-physiologic effects and clinical efficacy of flecainide in children with recurrent paroxysmal supraventricular tachycardia. Am J Cardiol 1988; 62: 229-33.
18. Till JA, Shinebourne EA, Rowland E, Ward DE, Bhamra R, Haga P, et al. Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics. Br Heart J 1989; 62: 133-9.
19. Hessling G, Brockmeier K, Ruediger HJ, Ulmer HE. Electrophysiologic effects and efficacy of intravenous propafenone in terminating atrioventricular reentrant tachycardia in children. Am J Cardiol 2001; 87: 802-4.
20. Reimer A, Paul T, Kallfelz HC.Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias. Am J Cardiol 1991; 69: 741-4.
21. Vignati G, Mauri L, Figini A. The use of propafenone in the treatment of tachyarrhythmias in children. Eur Heart J 1993; 14: 546-50.
22. Heusch A, Kramer HH, Krogmann ON, Rammos S, Bourgeous M. Clinical experience with propafenone for cardiac arrhythmias in the young. Eur Heart J 1994; 15: 1050-6.
23. Taketoma CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook. 13th Edition: Lexi-Comp Inc. 2006.
24. Saul JP, Scott WA, Brown S, Marantz P, Acevedo V, Etheridge SP, et al. Intravenous amiodarone for incessant tachyarrhythimias in children: A randomized, double-blind, antiarrhythmic drug trial. Circulation 2005; 112: 3470-7.
25. Ng GY, Hampson Evans DC, Murdoch LJ. Cardiovascular collapse after amiodarone administration in neonatal supraventicular tachycardia. Eur J Emerg Med 2003; 10: 323-5.
26. Bucknall CA, Keeton BR, Curry PV, Tynan MJ, Sutherland GR, Holt DW. Intravenous and oral amiodarone for arrhythmias in children Br Heart J 1986; 56: 278-84.
27. Figa FH, Gow RM, Hamilton RM, Freedom RM. Clinical efficacy and safely of intravenous Amiodarone in infants and children. Am J Cardiol 1994; 74: 573-7.
28. Perry JC, Fenrich AL, Hulse JE, Triedman JK, Friedman RA, Lamberti JJ. Pediatric use of intravenous amiodarone: Efficacy and safety in critically ill patients trom a multicenter protocol. J Am Coll Cardiol 1996; 27: 1246-50.
29. Adamson PC, Rhodes LA, Saul JP, Dick M, Epstein MR, Moate P, et al. The pharmacokinetics od esmolol in pediatric subjects with supraventricular arrhythmias. Pediatr Cardiol 2006; 27: 420-7.
30. Trippel DL, Weist DB, Gillette PC. Cardiovascular and antiarrhythmic effects of esmolol in children. J Pediatr 1991; 119: 142-7.
31. Gulamhusein S, Ko P, Carruthers SG, Klein GJ. Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation 1982; 65: 384-54.
32. McGovern B, Garan H, Ruskin JN. Precipitation of cardiac arrest by verapamil in patient with Wolff-Parkinson-White syndrome. Ann Intern Med 1986; 104(6): 791-4.
33. Epstein ML, Kiel EA, Victoria BE. Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia. Pediatrics 1985; 75: 737-40.
34. Wong KK, Potts JE, Etheridge SP, Sanatani S. Medications used to manage supraventricular tachycardia in the infant a North American survey. Pediatr Cardiol 2006; 27: 199-203.
35. Gillette P, Garson A Jr, Eterovic E, Neches W, Mullins C. McNamara DG. Oral propranolol treatment in infants and children. J Pediatr 1978; 92: 141-4.
36. Pickoff AS, Zies L, Ferrer PL, Tamer D, Wolff G, Garcia O, et al. High-dose propranolol therapy in the management of supraventricular tachycardia. J Pediatr 1979; 94: 144-6.
37. Trippel DL, Gillette PC. Atenolol in children with ventricular arrhythmias Am Heart J 1990; 119: 1312-6.
38. Mehta AV, Subrahmanyam AB, Anand R. Long-term efficacy and safety of atenolol for supraventricular tachycardia in children. Pediatr Cardiol 1996; 17: 231-6.
39. Ko JK, Ban JE, Kim YH, Park IS. Long-term efficacy of atenolol for atrioventricular reciprocating tachycardia in children less than 5 years old. Pediatr Cardiol 2004; 25: 97-101.
40. Mehta AV, Chidambaram B. Efficacy and safety of intravenous and oral nadolol for supraventricular tachycardia in children. J Am Coll Cardiol 1992; 19: 630-5.
41. Meht AV, Chidambaram B, Rice PJ. Pharmacokinetics of nadolol in children with supraventricular tachycardia. J Clin Pharmacol 1992; 32: 1023-7
42. Robrov VA, Frolov AI, Mitchenko YI, Chervonopiskaya YM, Galichansky IV. Comparative analysis of anti-arrhythmic effect of propranolol and metaprolol in patients with supraventricular tachyarrhythimas. Rev Port Carchol 1993; 12: 611-4.
43. Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: A clinical trial experience. J Pediatr 2007; 150: 134-9.
44. Wellens HJ, Durrer D. Effect of digitalis on atrioventricular conduction and circus-movement tachycardias in patients with Wolff-Parkinson-White syndrome. Circulation 1973; 47: 1229-33.
45. Byrum CJ, Wahl RA, Behrendt DM, Dick M. Ventricular fibrillation associated with use of degitalis in newborn infant with Wolff-Parkinson-White syndrome. J Pediatr 1982; 101: 400-3.
46. Deal BJ, Keane JF, Gillette PC, Garson A Jr. Wolff-Parkinson-White syndrome and supraventricular tachycardia during infancy: Management and follow-up. J Am Coll Cardiol 1985; 5: 130-5.
47. Perry JC, McQuinn RL, Smith RT Jr, Gothing C, Fredell P, Garson A Jr. Flecainide acetate for resistant arrhythimias in the young: Efficacy and pharmacokinetics. J Am Coll Cardiol 1989; 14: 185-91.
48. Van Engelen AD, Weijtens O, Brenner JL, Kleinman CS, Copel JA, Stoutenbeek P, et al. Management outcome and follow-up of fetal tachycardia. J Am Coll Cardiol 1994; 24: 1371-5.
49. Russell GA, Martin RP. Flecainide toxicity. Arch Dis Child 1989; 64: 860-2.
50. Zeigler V, Gillette PC, Hammill B, Ross BA, Ewing L. Flecamide for supraventricular tachycardia in children. Am J Cardiol 1988; 62: 41D-43D.
51. Fish FA, Gillette PC, Benson DW Jr. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. J Am Coll Cardiol 1991; 18: 356-65.
52. Musto B, D'Onofrio A, Cavallaro C, Musto A. Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia. Circulation 1988; 78: 863-9.
53. Janousek J, Paul T, Reimer A, Kallfelz HC. Usefalness of propafenone for supraventricular arrhythimas in infants and children. Am J Cardiol 1993; 72: 294-300.
54. Janousek J, Paul T. Safety of oral propafenone in the treatment of arrhythmias in infants and children. Am J Cardiol 1998; 81: 1121-4.
55. Saul JP, Ross B, Schaffer MS, Beerman L, Melikian AP, Shi J, et al. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia. Clin Pharmacol Ther 2001; 69: 145-57.
56. Maragnes P, Tipple M, Fournier A. Effectiveness of oral sotalol for treatment of pediatric arrhythmias. Am J Cardiol 1992; 69: 751-4.
57. Pfammatter JP, Paul T, Lehmann C, Kallfelz HC. Efficacy and proarrhythmia of oral sotalol in pediatric patients. J Am Coll Cardiol 1995; 26: 1002-7.
58. Tanel RE, Walsh EP, Lulu JA, Said JP. Sotalol for refractory arrhythmias in pediatric and young adult patients: Initial efficacy and long-term outcome. Am Heart J 1995; 130: 791-1.
59. Laer S, Elshoff JP, Meilbohm B, Weil J, Mir TS, Zhang W, et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 2005; 46: 1322-30.
60. Kunze KP, Schluter M, Ktick KH. Sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 1987; 75: 1050-7.
61. Touboul P, Atallah G, Kikorian G, Lavaud P, Mathie MP, Delinger A. Effects of intravenous sotalol in patients with atrioventricular accessory pathways. Am Heart J 1987; 114: 545-50.
62. Shahar E, Barzilay Z, Frand M, Feigl A. Amiodarone in control of sustained tachyarrhythmias in children with Wolff-Parkinson-White syndrome. Pediatrics 1983; 72: 813-6.
63. Ethertidge SP, Craig JE, Compton SJ. Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants. Am Heart J 2001; 141: 105-10.
64. Garson A Jr, Gillette PC, McVey P, Hesslein PS, Porter CJ, Angell LK, et al. Amiodarone treatment of critical arrhythimas in children and young adults. J Am Coll Cardiol 1984; 4: 749-55.
65. Coumel P, Fidelle J. Amiodarone in the treatment of cardiac arrhythmias in children: One hundred thirty-five cases. Am Heart J 1980; 100: 1063-9.
66. Guccione P, Paul T, Garson A Jr. Long-term follow-up of amiodarone therapy in the young: Continued efficacy, unimpaired growth, moderate side effects. J Am Cardiol 1990; 15: 1118-24.
67. Price JF, Kertesz NJ, Snyder CS, Friedman RA, Fenrich AL. Flecainide and sotalol: A new combination therapy for refractory supraventricular tachycardia in children <1 year of age. J Am Coll Cardiol 2002; 39: 517-20.
68. Gossinger HD, Siostrzonek P, Mosslacher H. Combined sotalol and flecainide given at low dosage in patients with the Wolff-Parkinson-White syndrome. Int J Cardiol 1990; 26: 380-2.
69. Fenrich AL Jr, Perry JC, Friedman RA. Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy. J Am Coll Cardiol 1995; 25: 1195-8.